ASRS 2020: In Neovascular AMD, Ranibizumab Maintains Improvement in Acuity for ≥36 Months
Treat-and-extend was compared with once-monthly dosing.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Treat-and-extend was compared with once-monthly dosing.
Only registered members have full access to PracticeUpdate content.